AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Related Articles
Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data – The Cancer Letter
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma…
How I treat sickle cell disease with gene therapy
New treatment options are becoming available for people with severe sickle cell disease with the US Food and Drug Administration’s approval of 2 autologous
A subset analysis of DREAMM-8: outcomes for patients who received 1 prior LOT including lenalidomide
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, comments on the results of a subset analysis of the DREAMM-8 study (NCT04484623), which investigated…
10 Questions With Kaitlyn Dykes | ASH News Daily | American Society of Hematology
Kaitlyn Dykes, MD, serves as chair of ASH’s Trainee Council. She is a third-year internal medicine resident at Georgetown University Hospital in Washington, DC. 1.…
Early adaptations to survive venetoclax therapy
In this issue of Blood, Luo et al1 enhance our understanding of the early adaptations of chronic lymphocytic leukemia (CLL) cells during the initial ramp-u
Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations.…
